Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram

Summary Background Guinea‐pig models can provide the essential features of asthma, including early‐ (EAR) and late‐ (LAR) phase asthmatic responses, airway hyper‐reactivity (AHR) and inflammatory cell influx; however, these components are rarely demonstrated all in the same model. Objectives The aim...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental allergy Vol. 34; no. 1; pp. 91 - 102
Main Authors Toward, T. J., Broadley, K. J.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.01.2004
Blackwell
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Summary Background Guinea‐pig models can provide the essential features of asthma, including early‐ (EAR) and late‐ (LAR) phase asthmatic responses, airway hyper‐reactivity (AHR) and inflammatory cell influx; however, these components are rarely demonstrated all in the same model. Objectives The aim of this study was to establish a conscious guinea‐pig model with these essential features of asthma and to correlate these with bronchoalveolar lavage fluid (BALF) histamine and nitric oxide (NO) levels. The model would be validated from the susceptibility of these parameters to standard anti‐asthmatic agents, the steroid, dexamethasone, and a phosphodiesterase‐4 (PDE4) inhibitor, rolipram. Methods Guinea‐pigs were sensitized with ovalbumen (OA) (10 μg plus Al2(OH)3 100 mg, intraperitoneal (i.p.)) and 14 days later received inhaled OA (100 μg/mL) or vehicle for 1 h. Airway function was measured by whole‐body plethysmography as specific airway conductance (sGaw). Reactivity to inhaled histamine (nose‐only, 1 mm, 20 s) was recorded 24 h before and at 6, 12 or 24 h after OA challenge. BALF was obtained to determine the total and differential cell counts, NO and histamine. Results Guinea‐pigs challenged with OA showed an EAR as a fall in (sGaw) (−54.9±10.8%), which resolved by 6 h and was followed by an LAR between 7 and 11 h (−30.2±8.8%). No bronchoconstriction to inhaled histamine occurred before OA challenge but at 6, 12 or 24 h afterwards, sGaw fell significantly, indicating AHR. At 1 h after OA, macrophages, eosinophils and neutrophils significantly increased in BALF. Macrophages and eosinophils increased further up to 24 h (3‐ and 44‐fold), but neutrophils declined to control levels. BALF histamine levels increased at 0.25 h after OA challenge and peaked at 6 h. BALF NO levels initially fell (44%) 1 h after OA exposure and then progressively rose above control levels. Dexamethasone (20 mg/kg, i.p.) and rolipram (1 mg/kg, i.p.) administered 24 and 0.5 h before and 6 h after OA challenge inhibited leucocyte influx, AHR and the early deficiency and later excess of NO. Dexamethasone but not rolipram attenuated the LAR. Conclusions This model displays many of the features of human asthma with predictable responses to dexamethasone and evidence of anti‐asthmatic activity by the PDE4 inhibitor, rolipram.
AbstractList Guinea-pig models can provide the essential features of asthma, including early- (EAR) and late- (LAR) phase asthmatic responses, airway hyper-reactivity (AHR) and inflammatory cell influx; however, these components are rarely demonstrated all in the same model. The aim of this study was to establish a conscious guinea-pig model with these essential features of asthma and to correlate these with bronchoalveolar lavage fluid (BALF) histamine and nitric oxide (NO) levels. The model would be validated from the susceptibility of these parameters to standard anti-asthmatic agents, the steroid, dexamethasone, and a phosphodiesterase-4 (PDE4) inhibitor, rolipram. Guinea-pigs were sensitized with ovalbumen (OA) (10 microg plus Al2(OH)3 100 mg, intraperitoneal (i.p.)) and 14 days later received inhaled OA (100 microg/mL) or vehicle for 1 h. Airway function was measured by whole-body plethysmography as specific airway conductance (sGaw). Reactivity to inhaled histamine (nose-only, 1 mm, 20 s) was recorded 24 h before and at 6, 12 or 24 h after OA challenge. BALF was obtained to determine the total and differential cell counts, NO and histamine. Guinea-pigs challenged with OA showed an EAR as a fall in (sGaw) (-54.9+/-10.8%), which resolved by 6 h and was followed by an LAR between 7 and 11 h (-30.2+/-8.8%). No bronchoconstriction to inhaled histamine occurred before OA challenge but at 6, 12 or 24 h afterwards, sGaw fell significantly, indicating AHR. At 1 h after OA, macrophages, eosinophils and neutrophils significantly increased in BALF. Macrophages and eosinophils increased further up to 24 h (3- and 44-fold), but neutrophils declined to control levels. BALF histamine levels increased at 0.25 h after OA challenge and peaked at 6 h. BALF NO levels initially fell (44%) 1 h after OA exposure and then progressively rose above control levels. Dexamethasone (20 mg/kg, i.p.) and rolipram (1 mg/kg, i.p.) administered 24 and 0.5 h before and 6 h after OA challenge inhibited leucocyte influx, AHR and the early deficiency and later excess of NO. Dexamethasone but not rolipram attenuated the LAR. This model displays many of the features of human asthma with predictable responses to dexamethasone and evidence of anti-asthmatic activity by the PDE4 inhibitor, rolipram.
Background Guinea-pig models can provide the essential features of asthma, including early- (EAR) and late- (LAR) phase asthmatic responses, airway hyper-reactivity (AHR) and inflammatory cell influx; however, these components are rarely demonstrated all in the same model. Objectives The aim of this study was to establish a conscious guineapig model with these essential features of asthma and to correlate these with bronchoalveolar lavage fluid (BALF) histamine and nitric oxide (NO) levels. The model would be validated from the susceptibility of these parameters to standard anti-asthmatic agents, the steroid, dexamethasone, and a phosphodiesterase-4 (PDE4) inhibitor, rolipram. Methods Guinea-pigs were sensitized with ovalbumen (OA) (10 mu g plus Al sub(2)(OH) sub(3) 100 mg, intraperitoneal (i.p.)) and 14 days later received inhaled OA (100 mu g/mL) or vehicle for 1 h. Airway function was measured by whole-body plethysmography as specific airway conductance (sG sub(aw)). Reactivity to inhaled histamine (nose-only, 1 mM, 20 s) was recorded 24 h before and at 6, 12 or 24 h after OA challenge. BALF was obtained to determine the total and differential cell counts, NO and histamine. Results Guinea-pigs challenged with OA showed an EAR as a fall in (sG sub(aw)) (-54.9 plus or minus 10.8%), which resolved by 6 h and was followed by an LAR between 7 and 11 h (-30.2 plus or minus 8.8%). No bronchoconstriction to inhaled histamine occurred before OA challenge but at 6, 12 or 24 h afterwards, sG sub(aw) fell significantly, indicating AHR. At 1 h after OA, macrophages, eosinophils and neutrophils significantly increased in BALF. Macrophages and eosinophils increased further up to 24 h (3- and 44-fold), but neutrophils declined to control levels. BALF histamine levels increased at 0.25 h after OA challenge and peaked at 6 h. BALF NO levels initially fell (44%) 1 h after OA exposure and then progressively rose above control levels. Dexamethasone (20 mg/kg, i.p.) and rolipram (1 mg/kg, i.p.) administered 24 and 0.5 h before and 6 h after OA challenge inhibited leucocyte influx, AHR and the early deficiency and later excess of NO. Dexamethasone but not rolipram attenuated the LAR. Conclusions This model displays many of the features of human asthma with predictable responses to dexamethasone and evidence of anti-asthmatic activity by the PDE4 inhibitor, rolipram.
BACKGROUNDGuinea-pig models can provide the essential features of asthma, including early- (EAR) and late- (LAR) phase asthmatic responses, airway hyper-reactivity (AHR) and inflammatory cell influx; however, these components are rarely demonstrated all in the same model. OBJECTIVESThe aim of this study was to establish a conscious guinea-pig model with these essential features of asthma and to correlate these with bronchoalveolar lavage fluid (BALF) histamine and nitric oxide (NO) levels. The model would be validated from the susceptibility of these parameters to standard anti-asthmatic agents, the steroid, dexamethasone, and a phosphodiesterase-4 (PDE4) inhibitor, rolipram. METHODSGuinea-pigs were sensitized with ovalbumen (OA) (10 microg plus Al2(OH)3 100 mg, intraperitoneal (i.p.)) and 14 days later received inhaled OA (100 microg/mL) or vehicle for 1 h. Airway function was measured by whole-body plethysmography as specific airway conductance (sGaw). Reactivity to inhaled histamine (nose-only, 1 mm, 20 s) was recorded 24 h before and at 6, 12 or 24 h after OA challenge. BALF was obtained to determine the total and differential cell counts, NO and histamine. RESULTSGuinea-pigs challenged with OA showed an EAR as a fall in (sGaw) (-54.9+/-10.8%), which resolved by 6 h and was followed by an LAR between 7 and 11 h (-30.2+/-8.8%). No bronchoconstriction to inhaled histamine occurred before OA challenge but at 6, 12 or 24 h afterwards, sGaw fell significantly, indicating AHR. At 1 h after OA, macrophages, eosinophils and neutrophils significantly increased in BALF. Macrophages and eosinophils increased further up to 24 h (3- and 44-fold), but neutrophils declined to control levels. BALF histamine levels increased at 0.25 h after OA challenge and peaked at 6 h. BALF NO levels initially fell (44%) 1 h after OA exposure and then progressively rose above control levels. Dexamethasone (20 mg/kg, i.p.) and rolipram (1 mg/kg, i.p.) administered 24 and 0.5 h before and 6 h after OA challenge inhibited leucocyte influx, AHR and the early deficiency and later excess of NO. Dexamethasone but not rolipram attenuated the LAR. CONCLUSIONSThis model displays many of the features of human asthma with predictable responses to dexamethasone and evidence of anti-asthmatic activity by the PDE4 inhibitor, rolipram.
Summary Background Guinea‐pig models can provide the essential features of asthma, including early‐ (EAR) and late‐ (LAR) phase asthmatic responses, airway hyper‐reactivity (AHR) and inflammatory cell influx; however, these components are rarely demonstrated all in the same model. Objectives The aim of this study was to establish a conscious guinea‐pig model with these essential features of asthma and to correlate these with bronchoalveolar lavage fluid (BALF) histamine and nitric oxide (NO) levels. The model would be validated from the susceptibility of these parameters to standard anti‐asthmatic agents, the steroid, dexamethasone, and a phosphodiesterase‐4 (PDE4) inhibitor, rolipram. Methods Guinea‐pigs were sensitized with ovalbumen (OA) (10 μg plus Al2(OH)3 100 mg, intraperitoneal (i.p.)) and 14 days later received inhaled OA (100 μg/mL) or vehicle for 1 h. Airway function was measured by whole‐body plethysmography as specific airway conductance (sGaw). Reactivity to inhaled histamine (nose‐only, 1 mm, 20 s) was recorded 24 h before and at 6, 12 or 24 h after OA challenge. BALF was obtained to determine the total and differential cell counts, NO and histamine. Results Guinea‐pigs challenged with OA showed an EAR as a fall in (sGaw) (−54.9±10.8%), which resolved by 6 h and was followed by an LAR between 7 and 11 h (−30.2±8.8%). No bronchoconstriction to inhaled histamine occurred before OA challenge but at 6, 12 or 24 h afterwards, sGaw fell significantly, indicating AHR. At 1 h after OA, macrophages, eosinophils and neutrophils significantly increased in BALF. Macrophages and eosinophils increased further up to 24 h (3‐ and 44‐fold), but neutrophils declined to control levels. BALF histamine levels increased at 0.25 h after OA challenge and peaked at 6 h. BALF NO levels initially fell (44%) 1 h after OA exposure and then progressively rose above control levels. Dexamethasone (20 mg/kg, i.p.) and rolipram (1 mg/kg, i.p.) administered 24 and 0.5 h before and 6 h after OA challenge inhibited leucocyte influx, AHR and the early deficiency and later excess of NO. Dexamethasone but not rolipram attenuated the LAR. Conclusions This model displays many of the features of human asthma with predictable responses to dexamethasone and evidence of anti‐asthmatic activity by the PDE4 inhibitor, rolipram.
Summary Background Guinea‐pig models can provide the essential features of asthma, including early‐ (EAR) and late‐ (LAR) phase asthmatic responses, airway hyper‐reactivity (AHR) and inflammatory cell influx; however, these components are rarely demonstrated all in the same model. Objectives The aim of this study was to establish a conscious guinea‐pig model with these essential features of asthma and to correlate these with bronchoalveolar lavage fluid (BALF) histamine and nitric oxide (NO) levels. The model would be validated from the susceptibility of these parameters to standard anti‐asthmatic agents, the steroid, dexamethasone, and a phosphodiesterase‐4 (PDE4) inhibitor, rolipram. Methods Guinea‐pigs were sensitized with ovalbumen (OA) (10 μg plus Al 2 (OH) 3 100 mg, intraperitoneal (i.p.)) and 14 days later received inhaled OA (100 μg/mL) or vehicle for 1 h. Airway function was measured by whole‐body plethysmography as specific airway conductance (sG aw ). Reactivity to inhaled histamine (nose‐only, 1 m m , 20 s) was recorded 24 h before and at 6, 12 or 24 h after OA challenge. BALF was obtained to determine the total and differential cell counts, NO and histamine. Results Guinea‐pigs challenged with OA showed an EAR as a fall in (sG aw ) (−54.9±10.8%), which resolved by 6 h and was followed by an LAR between 7 and 11 h (−30.2±8.8%). No bronchoconstriction to inhaled histamine occurred before OA challenge but at 6, 12 or 24 h afterwards, sG aw fell significantly, indicating AHR. At 1 h after OA, macrophages, eosinophils and neutrophils significantly increased in BALF. Macrophages and eosinophils increased further up to 24 h (3‐ and 44‐fold), but neutrophils declined to control levels. BALF histamine levels increased at 0.25 h after OA challenge and peaked at 6 h. BALF NO levels initially fell (44%) 1 h after OA exposure and then progressively rose above control levels. Dexamethasone (20 mg/kg, i.p.) and rolipram (1 mg/kg, i.p.) administered 24 and 0.5 h before and 6 h after OA challenge inhibited leucocyte influx, AHR and the early deficiency and later excess of NO. Dexamethasone but not rolipram attenuated the LAR. Conclusions This model displays many of the features of human asthma with predictable responses to dexamethasone and evidence of anti‐asthmatic activity by the PDE4 inhibitor, rolipram.
Author Broadley, K. J.
Toward, T. J.
Author_xml – sequence: 1
  givenname: T. J.
  surname: Toward
  fullname: Toward, T. J.
  organization: Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
– sequence: 2
  givenname: K. J.
  surname: Broadley
  fullname: Broadley, K. J.
  organization: Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15521189$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/14720268$$D View this record in MEDLINE/PubMed
BookMark eNqNks1u1DAUhSNURH_gFZCFBKtmsGM7iZFYVKOZglTBphR2luPcdDwk9tROaPJUvCJOZ9RKbMAbX937nSPbx6fJkXUWkgQRvCBxvd8uCM15msW1yDBmC0xKShfjs-TkcXCUnGDBWVqUgh0npyFsMcaUi_JFckxYkeEsL0-S3yvl2wkpW6NW9YAq76zeOO1s6L3RvYnFOVLG36sJbaYd-NSDiv1fpp_OUQuDdnqKQmObdhj3RoO9RRsTetUZCw8ta2Y35EZTx0bTg4-CjWqhjuPe3IL9gKBpQPcBuQbVMKoO-o0K7mDgXWt2XnUvk-eNagO8Ouxnybf16nr5Kb36evl5eXGVaiYITXMhGFOVIFWRq6oABrrOKpYTrkXWZCXT8cGqWtWUNsAYgaIQoIoiZ6XmIDA9S97tfXfe3Q0QetmZoKFtlQU3BFliLISg-T9BIjJecl5G8M1f4NYN3sZLREYIXFBGIlTuIe1dCB4aufOmU36SBMs5ermVc8JyTljO0cuH6OUYpa8P_kPVQf0kPGQdgbcHQAWt2sYrq0144jjPCClF5D7uuXvTwvTfB5DL1cVcRX2618cfAOOjXvmfMi9oweX3L5fy-sdNtl7fUInpHwyD3gA
CitedBy_id crossref_primary_10_1016_j_hrtlng_2008_01_002
crossref_primary_10_1016_j_pupt_2010_03_010
crossref_primary_10_3109_13880209_2015_1077465
crossref_primary_10_1113_JP280749
crossref_primary_10_1016_j_molimm_2013_11_006
crossref_primary_10_1007_BF02977330
crossref_primary_10_1007_s12272_001_1225_2
crossref_primary_10_1080_01902148_2017_1386735
crossref_primary_10_1002_ptr_3273
crossref_primary_10_1016_j_intimp_2008_01_025
crossref_primary_10_1016_j_ejphar_2005_12_060
crossref_primary_10_1016_j_intimp_2006_09_007
crossref_primary_10_1159_000502489
crossref_primary_10_1016_j_intimp_2009_10_009
crossref_primary_10_1124_jpet_117_241927
crossref_primary_10_3109_01902148_2014_985407
crossref_primary_10_1007_s11095_011_0454_1
crossref_primary_10_1016_j_ejphar_2017_03_004
crossref_primary_10_1016_j_pupt_2012_08_004
crossref_primary_10_1124_jpet_110_171876
crossref_primary_10_1042_CS20130130
crossref_primary_10_1063_1_3112143
crossref_primary_10_1017_S0265021507002591
crossref_primary_10_3109_02770903_2012_678958
crossref_primary_10_1016_j_pupt_2008_01_004
crossref_primary_10_1016_S1579_2129_06_60415_1
crossref_primary_10_1016_j_vascn_2014_10_007
crossref_primary_10_1097_MOL_0b013e328356b145
crossref_primary_10_1111_j_1476_5381_2012_01891_x
crossref_primary_10_1042_CS20200394
crossref_primary_10_1016_j_jconrel_2012_07_008
crossref_primary_10_1016_S0300_2896_05_70605_0
crossref_primary_10_1186_1472_6882_11_80
Cites_doi 10.1038/sj.bjp.0700901
10.1111/j.1476-5381.1981.tb08748.x
10.1111/j.1600-0773.1999.tb01495.x
10.1111/j.2042-7158.1970.tb08493.x
10.1164/ajrccm.162.2.9908132
10.1038/sj.bjp.0702372
10.1016/0014-2999(94)90369-7
10.1111/j.1398-9995.1993.tb04699.x
10.1159/000237207
10.1016/0006-2952(91)90056-B
10.1016/0091-6749(88)90077-2
10.1038/sj.bjp.0704191
10.1016/S0163-7258(02)00262-0
10.1007/BF00175942
10.1016/S0076-6879(96)68026-4
10.1111/j.1398-9995.1987.tb02223.x
10.1016/0014-2999(94)00749-W
10.1164/ajrccm/139.1.242
10.1164/ajrccm/136.2.369
10.1016/0160-5402(88)90025-3
10.1038/sj.bjp.0701738
10.1136/thx.48.2_Suppl.S1
10.1164/ajrccm.160.2.9807160
10.1183/109031936.95.08122104
10.1016/S0165-6147(00)01499-1
10.1038/sj.bjp.0702628
10.1136/thx.42.12.946
10.1016/S0014-2999(01)01333-4
10.1016/S0091-6749(94)70051-6
ContentType Journal Article
Copyright 2004 INIST-CNRS
Copyright Blackwell Scientific Publications Ltd. Jan 2004
Copyright_xml – notice: 2004 INIST-CNRS
– notice: Copyright Blackwell Scientific Publications Ltd. Jan 2004
DBID BSCLL
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T5
H94
K9.
7X8
DOI 10.1111/j.1365-2222.2004.01833.x
DatabaseName Istex
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
AIDS and Cancer Research Abstracts
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1365-2222
EndPage 102
ExternalDocumentID 546106771
10_1111_j_1365_2222_2004_01833_x
14720268
15521189
CEA1833
ark_67375_WNG_TXV2FFV3_0
Genre article
Research Support, Non-U.S. Gov't
Journal Article
General Information
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OB
1OC
29B
31~
33P
36B
3O-
3SF
4.4
4P2
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
A8Z
AAESR
AAEVG
AAHHS
AAKAS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
AOETA
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBB
EBC
EBD
EBS
EBX
EDH
EJD
EMB
EMK
EMOBN
ESTFP
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAJUZ
AAUGY
AAVGM
ABCVL
ABHUG
ABPTK
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
AKALU
IQODW
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T5
H94
K9.
7X8
ID FETCH-LOGICAL-c4913-69944ab91b76ab7e4ecd2b4615c92f284c183bdad33fe441e779ea77648c5e903
IEDL.DBID DR2
ISSN 0954-7894
IngestDate Fri Aug 16 21:00:39 EDT 2024
Sat Aug 17 01:15:22 EDT 2024
Thu Oct 10 18:12:52 EDT 2024
Fri Aug 23 03:27:51 EDT 2024
Sat Sep 28 08:35:20 EDT 2024
Sun Oct 22 16:04:22 EDT 2023
Sat Aug 24 00:52:12 EDT 2024
Wed Oct 30 09:51:37 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Allergy
allergen
Hyperreactivity
Psychotropic
Lung
Esterases
Phosphoric diester hydrolases
Respiratory system
Respiratory tract
Bronchoconstriction
Immunology
Antidepressant agent
Corticosteroid
Immunopathology
Late
3',5'-Cyclic-nucleotide phosphodiesterase
Dexamethasone
Enzyme
Steroid hormone
airway hyper-reactivity
Antiinflammatory agent
Enzyme inhibitor
guinea-pig airways
Inhalation
Antigen
Histamine
lung lavage
Rolipram
Nitric oxide
Hydrolases
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4913-69944ab91b76ab7e4ecd2b4615c92f284c183bdad33fe441e779ea77648c5e903
Notes istex:190578FA0010BEFB3EB418C41717196B926D1107
ArticleID:CEA1833
ark:/67375/WNG-TXV2FFV3-0
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 14720268
PQID 199907341
PQPubID 36521
PageCount 12
ParticipantIDs proquest_miscellaneous_80099936
proquest_miscellaneous_19258558
proquest_journals_199907341
crossref_primary_10_1111_j_1365_2222_2004_01833_x
pubmed_primary_14720268
pascalfrancis_primary_15521189
wiley_primary_10_1111_j_1365_2222_2004_01833_x_CEA1833
istex_primary_ark_67375_WNG_TXV2FFV3_0
PublicationCentury 2000
PublicationDate 2004-01
January 2004
2004
2004-Jan
2004-01-00
20040101
PublicationDateYYYYMMDD 2004-01-01
PublicationDate_xml – month: 01
  year: 2004
  text: 2004-01
PublicationDecade 2000
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Oxford
– name: England
PublicationTitle Clinical and experimental allergy
PublicationTitleAlternate Clin Exp Allergy
PublicationYear 2004
Publisher Blackwell Science Ltd
Blackwell
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Science Ltd
– name: Blackwell
– name: Wiley Subscription Services, Inc
References Toward TJ, Broadley KJ. Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea-pigs: effects of rolipram and dexamethasone. J Pharmacol Exp Ther 2001; 298: 298-306.
Torphy TJ. Phosphodiesterase isoenzymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-70.
Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med 2000; 162: 701-6.
Meurs H, Schuurman FE, Duyvendak M, Zaagsma J. Deficiency of nitric oxide in polycation-induced airway hyperreactivity. Br J Pharmacol 1999; 126: 559-62.
Barnes PJ, Adcock IM. NF-κB: a pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci 1997; 18: 46-51.
Sadeghi-Hashjin G, Folkerts G, Henricks PAJ et al. Peroxynitrite induces airway hyperresponsiveness in guinea-pigs in vitro and in vivo. Am J Respir Crit Care Med 1996; 151: 1250-4.
Schini-Kerth VB, Vanhoutte PM. Review article: nitric oxide synthases in vascular cells. Exp Physiol 1995; 80: 885-905.
Johnson A, Broadley KJ. Airway hyperresponsiveness in anaesthetised guinea-pigs 18-24 h after antigen inhalation dose not occur with all intravenous administered spasmogens. Pharmacol Toxicol 1998; 84: 281-7.
Santing RE, De Boer J, Rohof A, Van Der Zee NM, Zaagsma J. Bronchodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma. Eur J Pharmacol 2001; 429: 335-44.
Durham SR, Craddock CF, Cookson WO, Benson MK. Increases in airway responsiveness to histamine preceding allergen-induced late asthmatic responses. J Allergy Clin Immunol 1988; 82: 764-70.
Danahay H, Broadley KJ. Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitised guinea-pigs and airway leukocyte infiltration. Br J Pharmacol 1997; 120: 289-97.
Cockcroft DW. Allergen-induced increase in nonallergic airway responsiveness: a citation classic revisited. Can Respir J 2000; 7: 182-7.
Hicks R. The influence of corticosteroid pretreatment on anaphylactic bronchoconstriction in the guinea-pig. J Pharm Pharmacol 1970; 22: 170-9.
Nolte H, Schiotz O, Skov S. A new glass microfibre-based histamine analysis for allergy testing in children. Allergy 1987; 111: 366-73.
Feoktistov I, Polosa R, Holgate ST, Biaggioni I. Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol Sci 1998; 19: 148-53.
Bacon KB, Schall TJ. Chemokines as mediators in asthma. Int Arch Allergy Immunol 1996; 109: 97-109.
De Boer J, Meurs H, Flendring L, Zaagsma J. Role of nitric oxide and superoxide in allergen-induced airway hyperreactivity after the late asthmatic response in guinea-pigs. Br J Pharmacol 2001; 133: 1235-42.
Underwood S, Foster M, Raeburn D, Bottoms S, Karlsson JA. Timecourse of antigen-induced airway inflammation in the guinea-pig and its relationship to airway hyperresponsiveness. Eur Respir J 1995; 8: 2104-13.
Nijkamp FP, Folkerts G. Nitric oxide and bronchial hyperresponsiveness. Arch Int Pharmacodyn 1995; 329: 97-110.
Bousquet J, Jeffery P, Busse WW, Johnson M, Vignola AM. Asthma: from bronchoconstriction to airway inflammation and remodelling. Am J Respir Crit Care Med 2000; 161: 1720-45.
Rafferty P, Beasley R, Holgate ST. The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5′-monophosphate in atopic asthma. Am Rev Respir Dis 1987; 136: 369-73.
Colasanti M, Suzuki H. The dual personality of NO. Trends Pharmacol Sci 2000; 21: 249-52.
Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1999; 50: 515-75.
Dent G, Magnussen H, Rabe KF. Cyclic nucleotide phosphodiesterases in the human lung. Lung 1994; 172: 129-46.
Saleh D, Ernst P, Lim S, Barnes P, Giaid A. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticosteroids. FASEB J 1998; 12: 929-37.
Santing RE, Olymulder CG, Van der Molen K, Meurs H, Zaagsma J. Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs. Eur J Pharmacol 1995; 275: 75-82.
Schuiling M, Zuidhof AB, Bonouvrie MAA, Venema N, Zaagsma J, Meurs H. Role of nitric oxide in the development and partial reversal of allergen-induced airway hyperreactivity in conscious, unrestrained guinea-pigs. Br J Pharmacol 1998; 123: 1450-6.
Nevin B, Broadley KJ. Nitric oxide in respiratory diseases. Pharmacol Ther 2002; 95: 259-93.
Sugiura H, Ichinose I, Oyake T et al. Role of peroxynitrite in airway microvascular hyperpermeability during late allergic phase in guine-pigs. Am J Respir Crit Care Med 1999; 160: 663-71.
Finney MJ, Firsberg KJ. Quantification of nasal involvement in a guinea-pig plethysmograph. J Appl Physiol 76; 1994: 1432-8.
Torphy TJ, Barnette MS, Underwood DC et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999; 12: 131-5.
Santing RE, Oymulder CG, Zaagsma J, Meurs H. Relationships among allergen-induced early and late phase airway obstructions, bronchial hyperreactivity, and inflammation in conscious unrestrained guinea pigs. J Allergy Clin Immunol 1994; 96: 1021-30.
Santing RE, Schraa EO, Wachters A, Olymulder CG, Zaagsma J, Meurs H. Role of histamine in allergen-induced asthmatic reactions, bronchial hyperreactivity and inflammation in unrestrained guinea pigs. Eur J Pharmacol 1994; 254: 49-57.
Souness JE, Carter CM, Diocee BK, Hassall GA, Wood LJ, Turner NC. Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. Biochem Pharmacol 1991; 42: 937-45.
Pare PD, Hogg JC. Mechanics of airway narrowing. Am Rev Respir Dis 1989; 139: 242-6.
Curzen N, Rafferty P, Holgate ST. Effects of cyclo-oxygenase inhibitor, flurbiprofen, and an H1 histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man. Thorax 1987; 42: 946-52.
Schuiling M, Zuidhof AB, Meurs H, Zaagsma J. Role of tachykinin NK2-receptor activation in the allergen-induced late asthmatic reaction, airway hyperreactivity and airway inflammatory cell influx in conscious, unrestrained guinea-pigs. Br J Pharmacol 1999; 127: 1030-8.
Frossard N, Landry Y, Pauli G, Ruckstuhl M. Effects of cyclic AMP- and GMP- phosphodiesterases on immunological release of histamine and on lung contraction. Br J Pharmacol 1981; 73: 933-8.
Howarth PH, Rodington AE, Montfort S. Pathophysiology of asthma. Allergy 1993; 48: 50-6.
Smith L, Mcfadden ER Jr. Bronchial hyperreactivity revisited. Ann Allergy Asthma Immunol 1995; 74: 454-69.
Griffiths-Johnson DA, Nicholls PJ, Mcdermott M. Measurement of specific airways conductance in guinea-pigs. A non-invasive method. J Pharmacol Methods 1988; 19: 233-42.
Grisham MB, Johnson GG, Lancaster JR. Quantification of nitrate and nitrite in extracellular fluids. Methods Enzymol 1996; 268: 237-46.
British thoracic society guidelines on the management of asthma. Thorax 1993; 48: S1-24.
1993; 48
1995; 74
1994; 254
1996; 109
1989; 139
1988; 19
2002; 95
2000; 21
1994; 172
2000; 7
1996
1995; 275
1998; 84
1996; 268
1998; 157
2001; 429
1999; 126
1999; 127
1995; 8
76; 1994
2001; 133
2001; 298
1987; 42
1998; 19
1995; 80
1987; 111
1987; 136
1997; 120
1999; 160
1991; 42
1995; 329
1996; 151
2000; 161
1999; 12
1970; 22
1997; 18
2000; 162
1999; 50
1988; 82
1998; 123
1981; 73
1998; 12
1994; 96
e_1_2_6_31_2
e_1_2_6_30_2
Torphy TJ (e_1_2_6_20_2) 1999; 12
Saleh D (e_1_2_6_16_2) 1998; 12
e_1_2_6_18_2
e_1_2_6_19_2
Sadeghi‐Hashjin G (e_1_2_6_14_2) 1996; 151
Cockcroft DW. (e_1_2_6_5_2) 2000; 7
e_1_2_6_12_2
e_1_2_6_35_2
e_1_2_6_13_2
e_1_2_6_34_2
e_1_2_6_10_2
Finney MJ (e_1_2_6_32_2); 1994
e_1_2_6_11_2
e_1_2_6_39_2
e_1_2_6_38_2
e_1_2_6_15_2
Motulsky H. (e_1_2_6_36_2) 1996
Bousquet J (e_1_2_6_2_2) 2000; 161
Schini‐Kerth VB (e_1_2_6_9_2) 1995; 80
e_1_2_6_41_2
Nijkamp FP (e_1_2_6_42_2) 1995; 329
Torphy TJ. (e_1_2_6_17_2) 1998; 157
e_1_2_6_8_2
e_1_2_6_7_2
Barnes PJ (e_1_2_6_40_2) 1997; 18
e_1_2_6_29_2
Barnes PJ (e_1_2_6_3_2) 1999; 50
e_1_2_6_6_2
Feoktistov I (e_1_2_6_37_2) 1998; 19
e_1_2_6_24_2
e_1_2_6_23_2
e_1_2_6_22_2
e_1_2_6_21_2
e_1_2_6_28_2
e_1_2_6_43_2
Smith L (e_1_2_6_4_2) 1995; 74
e_1_2_6_27_2
e_1_2_6_44_2
e_1_2_6_26_2
e_1_2_6_45_2
e_1_2_6_25_2
Toward TJ (e_1_2_6_33_2) 2001; 298
References_xml – volume: 21
  start-page: 249
  year: 2000
  end-page: 52
  article-title: The dual personality of NO
  publication-title: Trends Pharmacol Sci
– volume: 157
  start-page: 351
  year: 1998
  end-page: 70
  article-title: Phosphodiesterase isoenzymes
  publication-title: molecular targets for novel antiasthma agents
– volume: 19
  start-page: 233
  year: 1988
  end-page: 42
  article-title: Measurement of specific airways conductance in guinea‐pigs. A non‐invasive method
  publication-title: J Pharmacol Methods
– volume: 8
  start-page: 2104
  year: 1995
  end-page: 13
  article-title: Timecourse of antigen‐induced airway inflammation in the guinea‐pig and its relationship to airway hyperresponsiveness
  publication-title: Eur Respir J
– volume: 160
  start-page: 663
  year: 1999
  end-page: 71
  article-title: Role of peroxynitrite in airway microvascular hyperpermeability during late allergic phase in guine‐pigs
  publication-title: Am J Respir Crit Care Med
– volume: 139
  start-page: 242
  year: 1989
  end-page: 6
  article-title: Mechanics of airway narrowing
  publication-title: Am Rev Respir Dis
– volume: 48
  start-page: S1
  year: 1993
  end-page: 24
  article-title: British thoracic society guidelines on the management of asthma
  publication-title: Thorax
– volume: 82
  start-page: 764
  year: 1988
  end-page: 70
  article-title: Increases in airway responsiveness to histamine preceding allergen‐induced late asthmatic responses
  publication-title: J Allergy Clin Immunol
– volume: 19
  start-page: 148
  year: 1998
  end-page: 53
  article-title: Adenosine A receptors
  publication-title: a novel therapeutic target in asthma?
– volume: 161
  start-page: 1720
  year: 2000
  end-page: 45
  article-title: Asthma
  publication-title: from bronchoconstriction to airway inflammation and remodelling
– volume: 136
  start-page: 369
  year: 1987
  end-page: 73
  article-title: The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5′‐monophosphate in atopic asthma
  publication-title: Am Rev Respir Dis
– volume: 96
  start-page: 1021
  year: 1994
  end-page: 30
  article-title: Relationships among allergen‐induced early and late phase airway obstructions, bronchial hyperreactivity, and inflammation in conscious unrestrained guinea pigs
  publication-title: J Allergy Clin Immunol
– volume: 172
  start-page: 129
  year: 1994
  end-page: 46
  article-title: Cyclic nucleotide phosphodiesterases in the human lung
  publication-title: Lung
– volume: 18
  start-page: 46
  year: 1997
  end-page: 51
  article-title: NF‐κB
  publication-title: a pivotal role in asthma and a new target for therapy
– volume: 12
  start-page: 131
  year: 1999
  end-page: 5
  article-title: Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD
  publication-title: from concept to clinic
– volume: 80
  start-page: 885
  year: 1995
  end-page: 905
  article-title: Review article
  publication-title: nitric oxide synthases in vascular cells
– volume: 151
  start-page: 1250
  year: 1996
  end-page: 4
  article-title: Peroxynitrite induces airway hyperresponsiveness in guinea‐pigs and
  publication-title: Am J Respir Crit Care Med
– volume: 42
  start-page: 946
  year: 1987
  end-page: 52
  article-title: Effects of cyclo‐oxygenase inhibitor, flurbiprofen, and an H histamine receptor antagonist, terfenadine, alone and in combination on allergen induced immediate bronchoconstriction in man
  publication-title: Thorax
– volume: 429
  start-page: 335
  year: 2001
  end-page: 44
  article-title: Bronchodilatory and anti‐inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma
  publication-title: Eur J Pharmacol
– start-page: 207
  year: 1996
  end-page: 84
– volume: 109
  start-page: 97
  year: 1996
  end-page: 109
  article-title: Chemokines as mediators in asthma
  publication-title: Int Arch Allergy Immunol
– volume: 127
  start-page: 1030
  year: 1999
  end-page: 8
  article-title: Role of tachykinin NK2‐receptor activation in the allergen‐induced late asthmatic reaction, airway hyperreactivity and airway inflammatory cell influx in conscious, unrestrained guinea‐pigs
  publication-title: Br J Pharmacol
– volume: 133
  start-page: 1235
  year: 2001
  end-page: 42
  article-title: Role of nitric oxide and superoxide in allergen‐induced airway hyperreactivity after the late asthmatic response in guinea‐pigs
  publication-title: Br J Pharmacol
– volume: 111
  start-page: 366
  year: 1987
  end-page: 73
  article-title: A new glass microfibre‐based histamine analysis for allergy testing in children
  publication-title: Allergy
– volume: 298
  start-page: 298
  year: 2001
  end-page: 306
  article-title: Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea‐pigs
  publication-title: effects of rolipram and dexamethasone
– volume: 42
  start-page: 937
  year: 1991
  end-page: 45
  article-title: Characterization of guinea‐pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation
  publication-title: Biochem Pharmacol
– volume: 22
  start-page: 170
  year: 1970
  end-page: 9
  article-title: The influence of corticosteroid pretreatment on anaphylactic bronchoconstriction in the guinea‐pig
  publication-title: J Pharm Pharmacol
– volume: 7
  start-page: 182
  year: 2000
  end-page: 7
  article-title: Allergen‐induced increase in nonallergic airway responsiveness
  publication-title: a citation classic revisited
– volume: 268
  start-page: 237
  year: 1996
  end-page: 46
  article-title: Quantification of nitrate and nitrite in extracellular fluids
  publication-title: Methods Enzymol
– volume: 84
  start-page: 281
  year: 1998
  end-page: 7
  article-title: Airway hyperresponsiveness in anaesthetised guinea‐pigs 18–24 h after antigen inhalation dose not occur with all intravenous administered spasmogens
  publication-title: Pharmacol Toxicol
– volume: 48
  start-page: 50
  year: 1993
  end-page: 6
  article-title: Pathophysiology of asthma
  publication-title: Allergy
– volume: 329
  start-page: 97
  year: 1995
  end-page: 110
  article-title: Nitric oxide and bronchial hyperresponsiveness
  publication-title: Arch Int Pharmacodyn
– volume: 275
  start-page: 75
  year: 1995
  end-page: 82
  article-title: Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs
  publication-title: Eur J Pharmacol
– volume: 254
  start-page: 49
  year: 1994
  end-page: 57
  article-title: Role of histamine in allergen‐induced asthmatic reactions, bronchial hyperreactivity and inflammation in unrestrained guinea pigs
  publication-title: Eur J Pharmacol
– volume: 73
  start-page: 933
  year: 1981
  end-page: 8
  article-title: Effects of cyclic AMP‐ and GMP‐ phosphodiesterases on immunological release of histamine and on lung contraction
  publication-title: Br J Pharmacol
– volume: 126
  start-page: 559
  year: 1999
  end-page: 62
  article-title: Deficiency of nitric oxide in polycation‐induced airway hyperreactivity
  publication-title: Br J Pharmacol
– volume: 162
  start-page: 701
  year: 2000
  end-page: 6
  article-title: Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways
  publication-title: Am J Respir Crit Care Med
– volume: 120
  start-page: 289
  year: 1997
  end-page: 97
  article-title: Effects of inhibitors of phosphodiesterase, on antigen‐induced bronchial hyperreactivity in conscious sensitised guinea‐pigs and airway leukocyte infiltration
  publication-title: Br J Pharmacol
– volume: 1994
  start-page: 1432
  year: 76
  end-page: 8
  article-title: Quantification of nasal involvement in a guinea‐pig plethysmograph
  publication-title: J Appl Physiol
– volume: 50
  start-page: 515
  year: 1999
  end-page: 75
  article-title: Inflammatory mediators of asthma
  publication-title: an update
– volume: 123
  start-page: 1450
  year: 1998
  end-page: 6
  article-title: Role of nitric oxide in the development and partial reversal of allergen‐induced airway hyperreactivity in conscious, unrestrained guinea‐pigs
  publication-title: Br J Pharmacol
– volume: 12
  start-page: 929
  year: 1998
  end-page: 37
  article-title: Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase
  publication-title: effect of inhaled glucocorticosteroids
– volume: 95
  start-page: 259
  year: 2002
  end-page: 93
  article-title: Nitric oxide in respiratory diseases
  publication-title: Pharmacol Ther
– volume: 74
  start-page: 454
  year: 1995
  end-page: 69
  article-title: Bronchial hyperreactivity revisited
  publication-title: Ann Allergy Asthma Immunol
– ident: e_1_2_6_22_2
  doi: 10.1038/sj.bjp.0700901
– ident: e_1_2_6_41_2
  doi: 10.1111/j.1476-5381.1981.tb08748.x
– volume: 7
  start-page: 182
  year: 2000
  ident: e_1_2_6_5_2
  article-title: Allergen‐induced increase in nonallergic airway responsiveness
  publication-title: a citation classic revisited
  contributor:
    fullname: Cockcroft DW.
– start-page: 207
  volume-title: Intuitive Biostatistics
  year: 1996
  ident: e_1_2_6_36_2
  contributor:
    fullname: Motulsky H.
– volume: 19
  start-page: 148
  year: 1998
  ident: e_1_2_6_37_2
  article-title: Adenosine A2B receptors
  publication-title: a novel therapeutic target in asthma?
  contributor:
    fullname: Feoktistov I
– volume: 298
  start-page: 298
  year: 2001
  ident: e_1_2_6_33_2
  article-title: Chronic lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea‐pigs
  publication-title: effects of rolipram and dexamethasone
  contributor:
    fullname: Toward TJ
– volume: 329
  start-page: 97
  year: 1995
  ident: e_1_2_6_42_2
  article-title: Nitric oxide and bronchial hyperresponsiveness
  publication-title: Arch Int Pharmacodyn
  contributor:
    fullname: Nijkamp FP
– ident: e_1_2_6_24_2
  doi: 10.1111/j.1600-0773.1999.tb01495.x
– ident: e_1_2_6_27_2
  doi: 10.1111/j.2042-7158.1970.tb08493.x
– ident: e_1_2_6_43_2
  doi: 10.1164/ajrccm.162.2.9908132
– volume: 12
  start-page: 131
  year: 1999
  ident: e_1_2_6_20_2
  article-title: Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD
  publication-title: from concept to clinic
  contributor:
    fullname: Torphy TJ
– ident: e_1_2_6_44_2
  doi: 10.1038/sj.bjp.0702372
– volume: 12
  start-page: 929
  year: 1998
  ident: e_1_2_6_16_2
  article-title: Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase
  publication-title: effect of inhaled glucocorticosteroids
  contributor:
    fullname: Saleh D
– volume: 1994
  start-page: 1432
  ident: e_1_2_6_32_2
  article-title: Quantification of nasal involvement in a guinea‐pig plethysmograph
  publication-title: J Appl Physiol
  contributor:
    fullname: Finney MJ
– volume: 161
  start-page: 1720
  year: 2000
  ident: e_1_2_6_2_2
  article-title: Asthma
  publication-title: from bronchoconstriction to airway inflammation and remodelling
  contributor:
    fullname: Bousquet J
– ident: e_1_2_6_26_2
  doi: 10.1016/0014-2999(94)90369-7
– volume: 18
  start-page: 46
  year: 1997
  ident: e_1_2_6_40_2
  article-title: NF‐κB
  publication-title: a pivotal role in asthma and a new target for therapy
  contributor:
    fullname: Barnes PJ
– ident: e_1_2_6_39_2
  doi: 10.1111/j.1398-9995.1993.tb04699.x
– ident: e_1_2_6_38_2
  doi: 10.1159/000237207
– ident: e_1_2_6_19_2
  doi: 10.1016/0006-2952(91)90056-B
– ident: e_1_2_6_6_2
  doi: 10.1016/0091-6749(88)90077-2
– ident: e_1_2_6_13_2
  doi: 10.1038/sj.bjp.0704191
– ident: e_1_2_6_12_2
  doi: 10.1016/S0163-7258(02)00262-0
– ident: e_1_2_6_18_2
  doi: 10.1007/BF00175942
– ident: e_1_2_6_35_2
  doi: 10.1016/S0076-6879(96)68026-4
– ident: e_1_2_6_34_2
  doi: 10.1111/j.1398-9995.1987.tb02223.x
– volume: 151
  start-page: 1250
  year: 1996
  ident: e_1_2_6_14_2
  article-title: Peroxynitrite induces airway hyperresponsiveness in guinea‐pigs in vitro and in vivo
  publication-title: Am J Respir Crit Care Med
  contributor:
    fullname: Sadeghi‐Hashjin G
– ident: e_1_2_6_28_2
  doi: 10.1016/0014-2999(94)00749-W
– ident: e_1_2_6_31_2
  doi: 10.1164/ajrccm/139.1.242
– ident: e_1_2_6_7_2
  doi: 10.1164/ajrccm/136.2.369
– volume: 80
  start-page: 885
  year: 1995
  ident: e_1_2_6_9_2
  article-title: Review article
  publication-title: nitric oxide synthases in vascular cells
  contributor:
    fullname: Schini‐Kerth VB
– ident: e_1_2_6_30_2
  doi: 10.1016/0160-5402(88)90025-3
– ident: e_1_2_6_11_2
  doi: 10.1038/sj.bjp.0701738
– ident: e_1_2_6_15_2
  doi: 10.1136/thx.48.2_Suppl.S1
– ident: e_1_2_6_25_2
  doi: 10.1164/ajrccm.160.2.9807160
– volume: 50
  start-page: 515
  year: 1999
  ident: e_1_2_6_3_2
  article-title: Inflammatory mediators of asthma
  publication-title: an update
  contributor:
    fullname: Barnes PJ
– ident: e_1_2_6_21_2
  doi: 10.1183/109031936.95.08122104
– ident: e_1_2_6_10_2
  doi: 10.1016/S0165-6147(00)01499-1
– volume: 157
  start-page: 351
  year: 1998
  ident: e_1_2_6_17_2
  article-title: Phosphodiesterase isoenzymes
  publication-title: molecular targets for novel antiasthma agents
  contributor:
    fullname: Torphy TJ.
– ident: e_1_2_6_45_2
  doi: 10.1038/sj.bjp.0702628
– volume: 74
  start-page: 454
  year: 1995
  ident: e_1_2_6_4_2
  article-title: Bronchial hyperreactivity revisited
  publication-title: Ann Allergy Asthma Immunol
  contributor:
    fullname: Smith L
– ident: e_1_2_6_8_2
  doi: 10.1136/thx.42.12.946
– ident: e_1_2_6_29_2
  doi: 10.1016/S0014-2999(01)01333-4
– ident: e_1_2_6_23_2
  doi: 10.1016/S0091-6749(94)70051-6
SSID ssj0003598
Score 1.9734586
Snippet Summary Background Guinea‐pig models can provide the essential features of asthma, including early‐ (EAR) and late‐ (LAR) phase asthmatic responses, airway...
Guinea-pig models can provide the essential features of asthma, including early- (EAR) and late- (LAR) phase asthmatic responses, airway hyper-reactivity (AHR)...
Background Guinea-pig models can provide the essential features of asthma, including early- (EAR) and late- (LAR) phase asthmatic responses, airway...
BACKGROUNDGuinea-pig models can provide the essential features of asthma, including early- (EAR) and late- (LAR) phase asthmatic responses, airway...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 91
SubjectTerms Administration, Inhalation
airway hyper-reactivity
allergen
Allergic diseases
Animals
Antigens - administration & dosage
Asthma - drug therapy
Asthma - immunology
Biological and medical sciences
Bronchial Hyperreactivity - drug therapy
Bronchoalveolar Lavage Fluid - chemistry
Bronchoalveolar Lavage Fluid - immunology
dexamethasone
Dexamethasone - therapeutic use
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Glucocorticoids - therapeutic use
Guinea Pigs
guinea-pig airways
histamine
Histamine - analysis
Immunopathology
Leukocytes - immunology
lung lavage
Male
Medical sciences
Models, Animal
nitric oxide
Nitric Oxide - analysis
rolipram
Rolipram - therapeutic use
Title Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram
URI https://api.istex.fr/ark:/67375/WNG-TXV2FFV3-0/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2222.2004.01833.x
https://www.ncbi.nlm.nih.gov/pubmed/14720268
https://www.proquest.com/docview/199907341
https://search.proquest.com/docview/19258558
https://search.proquest.com/docview/80099936
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxELZQKxAXCgXKUig-IE7daH-86zW3qjRUSO0BtSU3y3-rRmmTapOIhBOPwKvwSjwJM_YmIahICJFTtOuxtfZ4_I09_oaQ15lIXGGLJK40L2NW42VlKBhzxnLmUu4Kh1sDJ6fl8Tn70Ct6bfwT3oUJ_BDLDTecGd5e4wRXerw-yX2EFvy8m9dJQDvzDuLJNOcY3fXu44pJConqAu0ei3kl2HpQz60Vra1Um9jpM4ycVGPovDpkvbgNlq6jXL9MdbfIYPGBITpl0JlOdMd8-Y378f_0wEPyoEWz9CCo3yNyxw23yd2Q33K-Te6dtCf3j8l3z6RM1dDSK4C3VDejIVheg_C06fvLFeN9qvrNZzWnl-AcNz--fgNAa0J2i3165aZgu-cg2se8KrNQFZgqipTJ6hpa8Y_AREF9dDTrW3iAGdBB4BKWQQuvJ8g9-pa2QSx0VFPrZgqzaCvwO0IFmMboplHXT8h59-js8Dhu00XEhok0j0shGFNapKB1SnPHnLGZZgDZjMhqWIYNdI-2yuZ57QAFOs6FU5yXrDKFE0n-lGwMoa1nhAJmLKwx2kB5ltSJtlkmmBV4CJoq5SKSLlRD3gRWEPmLNwWjInFUMMcnk35U5Cwib7wOLQVUM8CoOl7IT6fv5VnvIut2L3KZRGRvTclWLRSAtdJKRGR3oXWytThjiXQSYK5ZGpFXy7dgKvD8Rw3daIpFMnAOi-rPJSrvMORlRHaCMq_aZjwDdx1kS6-Sf_3Z8vDoAP89_1fBXXI_REvhttcLsjFppu4lAMGJ3vNT_CfT51JH
link.rule.ids 315,783,787,1378,4031,27935,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELZQKx4XHuW1FFofEKdutA_ves2tKg0BmhxQWnKzvGuvGjXdVJtEJJz4CfwV_hK_hBl7kxBUJITIKdr1Q2vPjL-xx_MR8jISgUl0EvhZzlOflXhZGQr6nLGYmZCbxODWQLeXdk7Z-0EyaOiA8C6Myw-x2nBDzbD2GhUcN6Q3tdyGaMHP-nmtAMQzbgGg3Abtj5HH4c3HdS4pTFXnEu8xn2eCbYb1XNvSxlq1jcM-x9hJNYHhKx3vxXXAdBPn2oWqfY-Mlp_o4lMuWrNp3iq-_Jb98T-NwX1ytwG09NBJ4ANyw1Q75KajuFzskFvd5vD-IflukylTVWk6AoRL83pcgfEtEKHWQ3u_YnJA1bD-rBb0HPzj-sfXb4BpC0dwcUBHZgbmewFVh0itMndNgbWimDVZXUIv9hFYKWiPjudDDQ-QBB0qnMNKqOH1FNOPvqZNHAsdl1SbuUIibQWuh2sAmYyuanX5iJy2j_tHHb9hjPALJsLYT4VgTOUiBMFTOTfMFDrKGaC2QkQlrMQFDE-ulY7j0gAQNJwLozhPWVYkRgTxY7JVQV9PCQXYmOiiyAsoz4IyyHUUCaYFnoOGShmPhEvZkFcuMYj8xaGCWZE4K0jzyaSdFTn3yCsrRKsKqr7AwDqeyE-9t7I_OIva7bNYBh7Z25CydQ8JwK0wEx7ZXYqdbIzORGJGCbDYLPTI_uotWAs8AlKVGc-wSAT-YZL9uURmfYY49cgTJ83rvhmPwGOHuqmVyb_-bHl0fIj_nv1rxX1yu9PvnsiTd70Pu-SOC57CXbDnZGtaz8wLwIXTfM_q-0_Iz1Zf
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELZQKyouPMprKbQ-IE7daB_e9ZpbVRrKoxFCbcnN8tpeNUqbRJtEJJz4CfwV_hK_hBl7kxBUJITIKdr12Fp7PP7GHn9DyPNERDYzWRQWJc9DVuFlZSgYcsZSZmNuM4tbAyed_PiMve1m3Sb-Ce_CeH6I5YYbzgxnr3GCj0y1PsldhBb8nJvXikA70xbgyU2WAxBGgPRxRSWFTHWed4-FvBBsParn2prWlqpN7PUZhk6qMfRe5dNeXIdL12GuW6fad0h_8YU-PKXfmk7Klv7yG_nj_-mCu-R2A2fpgde_e-SGHWyTmz7B5XybbJ00R_f3yXdHpUzVwNBLwLe0rIcDML0a8Wndc7crxvtU9erPak4vwDuuf3z9BohW-_QW-_TSTsF4z0G0h4lVZr4qsFUUOZPVFbTiHoGNgvrocNYz8ABToIPABayDBl5PkHz0JW2iWOiwosbOFKbRVuB4-Aowj9GoVlcPyFn76PTwOGzyRYSaiTgNcyEYU6WIQe1UyS2z2iQlA8ymRVLBOqyhe0qjTJpWFmCg5VxYxXnOCp1ZEaUPycYA2npMKIDGzGhdaijPoioqTZIIZgSegsZK2YDEC9WQI08LIn9xp2BUJI4KJvlk0o2KnAXkhdOhpYCq-xhWxzP5qfNannbPk3b7PJVRQHbXlGzVQgZgKy5EQHYWWicbkzOWyCcB9prFAdlbvgVbgQdAamCHUyySgHeYFX8uUTiPIc0D8sgr86ptxhPw10E2dyr5158tD48O8N-TfxXcI1sfXrXl-zeddzvklo-cwi2wp2RjUk_tMwCFk3LXzfafeWZVDg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+and+late+bronchoconstrictions%2C+airway+hyper-reactivity%2C+leucocyte+influx+and+lung+histamine+and+nitric+oxide+after+inhaled+antigen%3A+effects+of+dexamethasone+and+rolipram&rft.jtitle=Clinical+and+experimental+allergy&rft.au=TOWARD%2C+T.+J&rft.au=BROADLEY%2C+K.+J&rft.date=2004&rft.pub=Blackwell&rft.issn=0954-7894&rft.eissn=1365-2222&rft.volume=34&rft.issue=1&rft.spage=91&rft.epage=102&rft_id=info:doi/10.1111%2Fj.1365-2222.2004.01833.x&rft.externalDBID=n%2Fa&rft.externalDocID=15521189
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-7894&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-7894&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-7894&client=summon